Economic implications of using bendamustine, alemtuzumab, or chlorambucil as a first-line therapy for chronic lymphocytic leukemia in the US: a cost-effectiveness analysis

by Kongnakorn T, Sterchele JA, Salvador CG, Getsios D, Mwamburi M
Published 2014-04-01